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Summary
Background.  —  The  renin-angiotensin-aldosterone  system  is  known  to  play  an  important  role
in the  pathophysiology  and  development  of  heart  failure.  Several  studies  have  reported  the
beneﬁts of  testosterone  in  heart  failure.  However,  the  mechanisms  of  testosterone-induced
effects on  heart  failure  require  further  study.
Aims.  —  To  determine  the  effects  of  castration  and  testosterone  administration  on  cardiac
function  and  angiotensin  II  receptor  function  in  rats  with  isoproterenol-induced  heart  failure.
Methods.  —  Wistar  rats  were  divided  randomly  into  control  and  heart  failure  groups.  The
heart failure  groups  were  further  divided  into  the  following  groups:  castration;  castra-
tion +  testosterone  replacement;  and  sham  castration.  Echocardiography  and  haemodynamic
measurements  were  used  to  evaluate  cardiac  function.  Cardiocyte  apoptosis  and  ﬁbrosis  were
determined  using  terminal  deoxyribonucleotide  transferase-mediated  dUTP  nick-end  labelling
(TUNEL)  staining  and  Masson’s  Trichrome  staining,  respectively.  Angiotensin  II  receptor  (AT1  and
AT2) messenger  ribonucleic  acid  (mRNA)  expression  levels  were  assayed  using  real-time  reverse
Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HF, heart failure; LV, left ventricle/ventricular; MRNA, messenger
ibonucleic acid; POD, peroxidase; PVDF, polyvinylidene diﬂuoride; RAAS, renin-angiotensin-aldosterone system; SDS-PAGE, sodium dodecyl
ulphate polyacrylamide gel electrophoresis; TUNEL, terminal deoxyribonucleotide transferase-mediated dUTP nick-end labelling; VW/BW,
entricular weight/body weight.
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transcriptase-polymerase  chain  reactions,  while  Western  immunoblotting  was  used  to  estimate
Bcl-2 protein  expression  levels.
Results.  —  Castration  signiﬁcantly  increased  cardiomyocyte  apoptosis  and  ﬁbrosis  that  was  nor-
mally induced  by  isoproterenol  (P  <  0.05).  AT2  receptor  mRNA  expression  in  the  castration
group was  increased  and  Bcl-2  protein  expression  was  decreased  compared  with  the  castra-
tion +  testosterone  replacement  group  (P  <  0.05).
Conclusion.  —  These  data  suggest  that  androgen  therapy  could  play  an  important  role  in  patho-
physiological  changes  in  heart  failure  and  have  beneﬁcial  effects  for  its  treatment.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  —  Le  système  rénine-angiotensine-aldostérone  joue  un  rôle  important  dans  la
physiopathologie  et  l’apparition  de  l’insufﬁsance  cardiaque.  De  nombreuses  études  ont  rapporté
les bénéﬁces  de  l’administration  de  testostérone  dans  l’insufﬁsance  cardiaque.  Cependant,  les
mécanismes  des  essais  induits  par  la  testostérone  dans  l’insufﬁsance  cardiaque  sont  mal  connus.
Objectif.  —  Déterminer  les  effets  de  la  castration  et  de  l’administration  de  testostérone  sur  la
fonction cardiaque  et  les  récepteurs  à  l’angiotensine  II  dans  un  modèle  expérimental  de  rats
avec induction  d’une  insufﬁsance  cardiaque  par  l’isoprotérénol.
Méthode.  —  Les  rats  Wistar  ont  été  divisés  de  fac¸on  randomisée  en  groupe  témoin  et  en  groupe
insufﬁsance  cardiaque.  Le  groupe  insufﬁsance  cardiaque  a  été  divisé  secondairement  en  sous-
groupes :  castration  ;  castration  +  substitution  testostérone  ;  et  castration  sham.  L’évaluation
échocardiographique  et  hémodynamique  de  la  fonction  cardiaque  a  été  effectuée.  L’apoptose
et la  ﬁbrose  ont  été  déterminées  en  utilisant  la  transferase  déoxyribonucléotide  terminale  :
(TUNEL) et  la  coloration  trichrome  Masson  respectivement.  L’expression  des  ARM  messagers
des récepteurs  de  l’angiotensine  II  (AT1  et  AT2)  a  été  évaluée  en  utilisant  les  techniques  de  PCR
sur la  transcriptase-polymerase  reverse, alors  que  l’immuomarquage  Western  a  été  utilisé  pour
évaluer les  niveaux  d’expression  de  la  protéine  Bcl-2.
Résultats.  —  La  castration  augmente  de  fac¸on  signiﬁcative  l’apoptose  des  cardiomyocytes  ainsi
que la  ﬁbrose  induit  par  l’isoprotérénol  (p  <  0,05).  L’expression  des  ARN  messager  du  récep-
teur à  l’angiotensine  2  AT2  dans  le  groupe  castration  est  augmentée  alors  que  l’expression
de la  protéine  Bcl-2  est  diminuée,  comparativement  au  groupe  castration  +  administration  de
testostérone  (p  <  0,05).
Conclusion.  — Ces  résultats  suggèrent  que  la  thérapie  androgénique  pourrait  jouer  un  rôle
important dans  les  modiﬁcations  physiopathologiques  observées  dans  l’insufﬁsance  cardiaque
et avoir  des  effets  bénéﬁques  pour  son  traitement.
© 2012  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Chronic  HF  is  a  major  health  problem  throughout  the  world
and  a  leading  cause  of  morbidity  and  mortality  [1].  Sex
differences  exist  when  determining  the  cause  of  cardio-
vascular  diseases.  Most  studies  have  examined  these  sex
differences  by  focusing  on  the  effects  of  oestrogen  on  car-
diovascular  function.  However,  numerous  additional  studies
have  indicated  that  androgens  can  also  have  an  effect  on
cardiovascular  function.  Testosterone  levels  are  decreased
in  men  with  HF,  while  testosterone  replacement  therapy  has
been  associated  with  signiﬁcant  increases  in  cardiac  out-
put  and  improved  functional  capacity  as  well  as  reduced
symptoms  in  men  with  HF  [2,3]. The  therapeutic  beneﬁts  of
testosterone  in  those  with  chronic  HF  can  be  attributed  to  a
number  of  factors.  For  example,  testosterone  has  vasodila-
tory  properties  and  acute  administration  has  been  shown
to  lower  peripheral  vascular  resistance,  reduce  cardiac
afterload  and  increase  the  cardiac  index.  In  addition,  testos-
terone  can  modulate  immune  responses  and  improve  insulin
resistance  while  also  exerting  its  effects  on  coagulation,
a
t
[
mbesity,  endothelial  function  and  alterations  in  skeletal  mus-
le  [3—5]. However,  the  exact  mechanisms  underlying  these
ffects  mediated  by  testosterone  on  HF  remain  unclear.
The  RAAS  is  known  to  play  an  important  role  in  the  patho-
hysiology  and  development  of  HF.  RASS  activity  is  increased
n  patients  with  HF,  which  could  lead  to  cardiac  remodelling
nd  sympathetic  activation.  Both  angiotensin  II  receptor
ype  1  (AT1  receptor)  and  angiotensin  II  receptor  type  2  (AT2
eceptor)  are  expressed  in  the  heart,  with  localization  on
ardiomyocytes  [6].  A  number  of  studies  have  indicated  that
ngiotensin  II  receptor  expression  is  altered  in  the  hearts  of
nimal  models  with  HF.  Moreover,  Nio  et  al.  [7]  reported  that
xpression  of  both  AT1  and  AT2  receptor  mRNA  was  upreg-
lated  in  the  infarcted  and  non-infarcted  portions  of  the  LV
ollowing  coronary  ligation.
A  number  of  interactions  between  androgens  and  RAAS
ave  been  shown  to  occur  at  several  organ  sites.  Androgens
nd  androgen  receptor  systems  are  known  to  exert  protec-
ive  effects  on  angiotensin  II-induced  vascular  remodelling
8].  Androgens  have  also  been  shown  to  affect  AT1a  receptor
RNA  abundance  in  the  abdominal  but  not  thoracic  aortas
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f  male  mice  [9].  Therefore,  the  purpose  of  the  present
tudy  was  to  determine  whether  changes  in  the  androgen
nvironment  could  induce  alterations  in  the  expression  and
ctivity  of  heart  angiotensin  II  receptors  in  HF.  Furthermore,
e  proposed  that  these  activities  of  angiotensin  II  receptors
re  involved  in  the  development  of  ﬁbrosis  and  apoptosis  in
ardiomyocytes  in  HF.
ethods
ll  procedures  were  performed  and  approved  in  accordance
ith  the  Institutional  Animal  Care  and  Use  Committee  at
arbin  Medical  University.  Male  Wistar  rats  were  obtained
rom  the  Laboratory  Animal  Centre  of  Harbin  Medical  Uni-
ersity  (Harbin,  China).  All  animals  were  maintained  on
tandard  rat  chow  and  water  ad  libitum  and  were  housed  in
he  Laboratory  Animal  Centre  under  conditions  of  controlled
mbient  temperature  (22—24 ◦C)  with  a  light-dark  cycle  of
2  h.
astration and hormone replacement
eventy  sexually  mature  male  rats  (7  weeks  of  age,
60—220  g)  were  used  in  this  study.  Ten  rats  were  ran-
omly  selected  for  the  control  group.  The  remaining
0  were  divided  into  three  equal  groups  randomly:  cas-
ration  +  placebo  (Cas+P);  sham  castration  (S-Cas);  and
astration  +  testosterone  replacement  (Cas+T);  Surgeries
ere  performed  while  the  rats  were  maintained  under  pen-
obarbital  sodium  anaesthesia  (60  mg/kg).  The  rats  were
laced  in  a  supine  position  and  the  testes  were  removed  via  a
idline  incision  in  the  lower  abdominal  wall.  Sham-operated
ats  received  a  midline  incision  that  was  immediately
losed.  For  rats  receiving  testosterone  propionate,  replace-
ent  was  initiated  on  the  ﬁrst  day  following  castration.
estosterone  propionate  (amino  acids,  P.F.,  Tianjin,  China)
as  administered  once  daily  (2  mg/kg  subcutaneously)  for
0  weeks.  Placebo  (saline)  was  administered  at  the  same
osage.  The  dosage  and  duration  of  treatments  were  based
pon  previously  described  protocols  and  data  from  prelimi-
ary  experiments  in  our  laboratory  [10].
nduction of heart failure
wo  weeks  postcastration,  isoproterenol  (Sigma-Aldrich,  St.
ouis,  MO,  USA)  was  administered  (340  mg/kg/day,  subcuta-
eously)  on  two  consecutive  days.  Excluding  controls,  all
ats  received  an  injection  of  isoproterenol.  Eight  weeks
ater,  the  numbers  in  the  four  groups  were:  Cas+P  (n  =  8);
-Cas  (n  =  9);  Cas+T  (n  =  10);  control  group  (n  =  10).
chocardiography and haemodynamic
easurements
en  weeks  postcastration  and  hormone  replacement,
ransthoracic  echocardiography  was  performed  while  the
ats  were  maintained  under  pentobarbital  sodium  anaes-
hesia  (60  mg/kg).  Two-dimensional  and  M-mode  images
ere  obtained  using  a  10  Mhz  transducer  connected  to  an
ltrasonic  echocardiographic  system  (Acuson  Sequoia  512;
iemens  AG,  Erlangen,  Germany).  Systolic  and  diastolic
l
p
t
mN.-N.  Kang  et  al.
imensions  of  the  LV  were  obtained  from  the  M-mode
iew.  Ejection  fraction  was  calculated  as  follows:  ejec-
ion  fraction  (%)  =  [(LVDV−LVSV)/LVDV]  ×  100,  where  LVDV
nd  LVSV  are  left  ventricular  end-diastolic  and  end-
ystolic  volumes,  respectively.  All  variables  were  measured
n  triplicate  and  averaged.  The  investigator  who  per-
ormed  the  echocardiograms  was  blinded  to  the  treatment
roup.
Haemodynamic  measurements  were  also  obtained  for
he  estimation  of  cardiac  function.  The  rats  were  anaes-
hetized  using  pentobarbital  sodium  (60  mg/kg)  and  allowed
o  breathe  room  air  spontaneously.  A  2  Fr  micromanometer-
ipped  catheter  ﬁlled  with  heparinized  saline  was  fed
hrough  the  right  carotid  artery  into  the  LV  and  connected  to
 pressure  transducer  (model  SPR-407;  Miller  Instruments,
ouston,  TX,  USA).  During  this  procedure,  LV  systolic  and
iastolic  pressures  and  maximal  rates  of  rise  and  fall  in  LV
ressure  were  recorded.  Resting  haemodynamic  measure-
ents  were  performed  in  triplicate  at  5  min  intervals  and  the
verage  values  of  these  triplicates  were  used  for  statistical
nalyses.
issue preparation and histological analysis
ollowing  haemodynamic  measurements,  harvested
ardiectomy  was  performed  and  the  hearts  were  weighed.
 small  portion  of  the  heart  was  snap  frozen  in  liquid
itrogen  and  stored  at  −80oC  until  biochemical  and  molec-
lar  analyses;  a  second  portion  of  the  heart  was  ﬁxed
n  4%  paraformaldehyde  overnight.  Following  ﬁxation,
amples  were  embedded  in  parafﬁn  and  4  m  sections
ere  cut  and  stained.  In  order  to  calculate  the  ratio
f  the  interstitial  ﬁbrosis  area  in  the  LV,  samples  were
tained  with  Masson’s  Trichrome  and  10  ﬁelds  were  selected
andomly  from  ﬁve  individual  sections.  The  percentage
f  ﬁbrotic  tissue  inﬁltration  in  the  LV  was  calculated  as
ollows:  (ﬁbrotic  tissue  area)/(ﬁbrotic  tissue  area  +  myocyte
rea)  × 100%.
nalysis of apoptosis
ardiomyocyte  apoptosis  was  measured  using  an  in  situ
UNEL  assay.  TUNEL  staining  was  performed  according  to
he  manufacturer’s  instructions  in  the  In  Situ  Cell  Death
etection  Kit,  POD  (Roche,  Basel,  Switzerland).  In  brief,  the
issue  sections  were  deparafﬁnized  and  rehydrated  using
ylene  and  graded  ethanol  dilutions  with  a  ﬁnal  rinse  in
istilled  water.  The  tissue  sections  were  then  pretreated
ith  20  mg/L  proteinase  K  for  30  min  and  incubated  in
he  TUNEL  reaction  mixture  in  a  humidiﬁed  cabinet  for
0  min  at  37 ◦C.  The  tissue  was  then  washed  in  0.1  M
hosphate  buffer  saline  in  triplicate  for  5  min  and  incu-
ated  in  converter-POD  for  30  min  at  37 ◦C.  Finally,  the
issues  were  washed  in  0.1  M  phosphate  buffer  saline  in
riplicate  for  5  min  and  stained  with  a diaminobenzidine-
OD  substrate  (Boster,  Wuhan,  China).  Tissue  sections  were
xamined  with  a  microscope  at  × 400  magniﬁcation  and  at
east  100  cells  were  counted  in  10  evenly  spaced  ﬁelds.  The
ercentage  of  apoptotic  cells  was  identiﬁed  as  the  apop-
otic  index.  All  measurements  were  performed  in  a  blind
anner.
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Real-time reverse transcriptase-polymerase
chain  reaction
Total  RNA  was  isolated  by  the  TRIZOL  technique  (Takara,
Otsu,  Shiga,  Japan)  according  to  the  manufacturer’s
instructions.  Samples  were  quantiﬁed  with  a  spectropho-
tometer  at  260  nm  and  integrity  was  determined  using
ethidium  bromide  agarose  gel  electrophoresis.  Reverse
transcription  was  performed  using  the  PrimeScriptTM
reverse  transcription  reagent  kit  (Takara,  Otsu,  Shiga,
Japan).  To  examine  mRNA  levels  of  the  AT1  recep-
tor  (primer  sequences  5′-CATCGTCCACCCAATGAAGTC-3′
and  5′-GGGAACAAGAAGCCCAGAAT-3′)  and  AT2  receptor
(primer  sequences  5′-CACAAACCGGCAGATAAGCA-3′ and  5′-
CAGGTCCAAAG-AGCCAGTCATA-3′)  quantitatively,  real-time
reverse  transcriptase-polymerase  chain  reaction  ampliﬁ-
cation  was  performed  using  a  SYBR  Premix  Ex  TaqTM
(Takara,  Otsu,  Shiga,  Japan).  Expression  of  GAPDH
(primer  sequences  5′-CAACG-ACCCCTTCATTGACC-3′ and
5′-GACGCCAGTAGACTCCACGAC-3′)  was  measured  as  an
internal  control  for  sample  variations  in  the  reverse  tran-
scription  reaction.
Western Blot analyses
Bcl-2  protein  expression  was  measured  using  Western
immunoblotting  as  previously  described  [10]. In  brief,  car-
diac  tissues  were  scraped  into  0.3  mL  lysis  buffer  (1%  Nonidet
P-40,  0.5%  sodium  deoxycholate,  0.1%  sodium  dodecyl  sul-
phate  [SDS],  100  g/mL  phenylmethylsulphonyl  ﬂuoride  and
30  g/mL  aprotinin)  and  incubated  for  30  min  on  ice.  Pro-
tein  concentrations  were  measured  using  a  Bio-Rad  Protein
Assay  Kit  (Bio-Rad,  Hercules,  CA,  USA).  Fifty  micrograms
of  protein  were  mixed  and  boiled  in  SDS  polyacrylamide
gel  electrophoresis  (SDS-PAGE)  sample  buffer  for  5  min  and
then  separated  on  SDS-PAGE  gels  (Bio-Rad,  Hercules,  CA,
USA).  Separated  proteins  were  transferred  to  a  PVDF  mem-
brane  and  were  probed  with  polyclonal  anti-Bcl-2  (1:1000)
and  anti-GAPDH  antibodies  (1:1000)  (Santa  Cruz  Biotech-
nology,  CA,  USA)  to  detect  target  protein  expression.  The
relative  amount  of  Bcl-2  was  determined  by  densitometry
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Table  1  Effect  of  testosterone  on  cardiac  function.
Control  (n  =  10) Cas+T  (n  =
VW/BW  (mg/g)  2.55  ±  0.14  2.76  ±
LVEDD  (mm)  5.3  ±  0.2  5.7  ±
EF  (%)  84.3  ±  3.8  71.3  ±
HR  (beats/min)  304  ±  33  352  ±
LVESP  (mmHg)  109.1  ±  4.1  96.9  ±
LVEDP  (mmHg)  4.9  ±  1.3  14.9  ±
+dP/dtmax (mmHg/s)  3966.6  ±  156.4  3327  ±
−dP/dtmax (mmHg/s)  −3730  ±  170.8  −3115.2  ±
All data are mean ± standard error of the mean. Cas+P: castration +
maximum peak rate of rise in left ventricular pressure; −dP/dt: max
fraction; HR: heart rate; LVEDD: left ventricular end-diastolic diame
ventricular end-systolic pressure; S-Cas+P: sham castration + placebo; V
* P < 0.05 versus control group.
** P < 0.05 versus Cas+P group.71
sing  ImageQuant  software,  with  protein  levels  of  GAPDH
sed  as  an  internal  control.
tatistical analyses
ata  are  presented  as  mean  ±  standard  error  of  the  mean.
fter  establishing  homogeneity  of  variance  and  normal  dis-
ribution,  a  one-way  analysis  of  variance  was  performed
o  determine  differences  among  groups.  If  the  analy-
is  of  variance  was  determined  to  be  signiﬁcant,  the
tudent-Newman-Keuls  test  was  used  for  post  hoc  pairwise
omparisons.  Statistical  signiﬁcance  was  deﬁned  as  P  <  0.05.
tatistical  analyses  of  data  were  performed  using  SPSS  sta-
istical  software  (version  14.0).
esults
nimal mortality
ortality  rates  in  the  Cas+P,  S-Cas  and  Cas+T  groups  were  60,
5  and  50%,  respectively,  following  isoproterenol  adminis-
ration.  There  were  no  signiﬁcant  differences  between  these
hree  groups  (P  >  0.05).
ody and heart weights
eft  ventricular  weight  normalized  to  body  weight  (VW/BW,
g/g)  was  signiﬁcantly  increased  in  each  of  the  HF  groups
all  P  <  0.05,  Table  1)  compared  with  in  the  control  group.
lthough  not  statistically  signiﬁcant,  castration  tended  to
ncrease  VW/BW,  which  was  alleviated  with  testosterone
eplacement.
ffect of testosterone on cardiac function
ats  in  each  of  the  treatment  groups  exhibited  a dilated
V,  as  indicated  by  an  increased  LV  end-diastolic  diame-
er  (P  <  0.05,  Table  1).  Ejection  fraction  was  also  altered
ithin  each  treatment  group  (P  <  0.05,  Table  1).  LV  end-
iastolic  diameter  was  signiﬁcantly  increased  in  castrated
ompared  with  sham-operated  rats  (P  <  0.05),  which  was
 10)  Cas+P  (n  =  8)  S-Cas+P  (n  = 9)
 0.09* 2.85  ±  0.17* 2.80  ±  0.15*
 0.4*,** 6.2  ±  0.4* 5.8  ±  0.3*,**
 5.5*,** 61.0  ±  5.6* 62.6  ±  5.4*
 31*,** 385  ±  28* 374  ±  41*
 5.7*,** 85  ±  6.4* 90.3  ±  4.1*
 2.8*,** 22.8  ±  5.4* 15.5  ±  2.2*,**
 204*,** 2786  ±  153.9* 3128  ±  234.6*,**
 216*,** −2648.9  ±  169.3* −2978.2  ±  208.6*,**
 placebo; Cas+T: castration + testosterone replacement; + dP/dt:
imum peak rate of fall in left ventricular pressure; EF: ejection
ter; LVEDP: left ventricular end-diastolic pressure; LVESP: left
W/BW: ventricular weight/body weight.
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eversed  with  testosterone  replacement  (P  <  0.05).  Testos-
erone  replacement  also  improved  cardiac  function  in  rats
ith  HF  (P  <  0.05).
Rats  with  induced  HF  exhibited  increased  LV  end-
iastolic  pressure  and  heart  rate,  and  decreased  LV
nd-systolic  pressure  and  peak  rate  of  change  in  LV  pres-
ure  (dP/dt),  compared  with  controls  (all  P  <  0.05,  Table  1).
he  LV  end-diastolic  pressure  of  rats  receiving  testosterone
eplacement  was  signiﬁcantly  decreased  compared  with
lacebo-treated  animals  (P  <  0.05).
ffects of testosterone on apoptosis and
ardiac ﬁbrosis
ig.  1  shows  TUNEL  staining  following  treatment  in  all  groups
n  =  8).  TUNEL-positive  nuclei  were  observed  in  the  HF  versus
A
t
g
s
igure 1. Effect of heart failure and testosterone therapy on cardiac a
taining (n = 8): (A) control; (B) Cas+P group; (C) S-Cas group; (D) Cas+
our groups: control group 0.22 ± 0.07; Cas+P group 2.28 ± 0.48; S-Cas 
ean ± standard error of the mean. *P < 0.05 versus control group; + P
astration + placebo; Cas+T: castration + testosterone replacement; S-CaN.-N.  Kang  et  al.
ontrol  groups  (P  <  0.05).  The  number  of  TUNEL-positive
uclei  in  cardiomyocytes  was  signiﬁcantly  lower  in  the  Cas+T
nd  S-Cas  groups  than  in  the  Cas+P  group  (P  <  0.05).  Fur-
hermore,  cardiomyocytes  from  the  Cas+T  group  were  more
redominant  than  in  the  S-Cas  group  (P  <  0.05).  Testosterone
eplacement  abrogated  the  development  of  ﬁbrosis  com-
ared  with  animals  in  the  Cas+P  and  S-Cas  groups  (P  < 0.05,
ig.  2).
ffects of testosterone on AT1 receptor and
T2 receptor gene expressionlthough  there  were  no  signiﬁcant  differences  in  AT2  recep-
or  mRNA  levels  between  the  Cas+T,  S-Cas  and  control
roups,  HF  tended  to  increase  AT2  receptor  mRNA  expres-
ion  (Cas+T/control  =  1.41,  S-Cas/control  =  2.2;  Fig.  3B).
poptosis. (A—D) representative photographs for myocardial TUNEL
T group. (E) quantitative analysis of TUNEL-positive cells in the
group 1.1 ± 0.22; Cas+T group 0.82 ± 0.12. Data are expressed as
 < 0.05 versus Cas+P group; P < 0.05 versus S-Cas group. Cas+P:
s: sham castration.
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Figure 2. Representative Masson’s Trichrome-stained images (n = 8): ﬁbrotic tissue, blue; residual myocytes, red. (A) control group; (B)
Cas+P group; (C) S-Cas group; (D) Cas+T group. (E) Percentage of ﬁbrotic tissue inﬁltration in the left ventricle from all groups: control group
0.35 ± 0.17; Cas+P group 10.7 ± 2.54; S-Cas group 6.5 ± 1.98; Cas+T group 2.55 ± 0.52. Data are expressed as mean ± standard error of the
as gr
i
m
D
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•
•
•mean. *P < 0.05 versus control group; + P < 0.05 versus Cas+P and S-C
replacement; S-Cas: sham castration.
Furthermore,  the  Cas+P  group  had  increased  AT2  recep-
tor  mRNA  levels  compared  with  the  control  group  (P  <  0.05,
Fig.  3B),  while  the  Cas+T  group  had  reduced  AT2  receptor
mRNA  levels  compared  with  the  Cas+P  group  (P  <  0.05).  HF
increased  AT1  receptor  mRNA  expression  (P  <  0.05)  but  there
were  no  statistically  signiﬁcant  differences  in  AT1  recep-
tor  mRNA  expression  between  the  Cas+T,  Cas+P  and  S-Cas
groups.  (P  >  0.05,  Fig.  3A).
Effects of testosterone on Bcl-2 protein
expressionWestern  immunoblot  analysis  of  Bcl-2  protein  expression
is  shown  in  Fig.  3C.  Isoproterenol  administration  caused  a
decrease  in  Bcl-2  protein  expression  (P  <  0.05).  In  the  Cas+P
group,  Bcl-2  protein  expression  was  decreased  further  than
•oups. Cas+P: castration + placebo; Cas+T: castration + testosterone
n  the  S-Cas  group  (P  <  0.05),  while  testosterone  replace-
ent  increased  Bcl-2  protein  expression  (P  <  0.05).
iscussion
n  the  present  study,  we  found  that:
castration  worsened  cardiac  function  of  rats  with  HF  and
testosterone  replacement  could  reduce  this  decrease  in
cardiac  function;
testosterone  replacement  reduced  the  extent  of  myocar-
dial  ﬁbrosis  in  HF  induced  with  isoproterenol;
castration  resulted  in  an  elevation  in  AT2  receptor  expres-
sion  but  these  changes  were  reduced  with  testosterone
replacement;
testosterone  replacement  decreased  cardiac  cell  apop-
tosis  that  was  induced  with  isoproterenol  and  increased
Bcl-2  protein  expression.
74  
Figure 3. Effect of testosterone on levels of expression of
angiotensin II receptor (AT1 and AT2) mRNA and Bcl-2 protein. (A)
levels of expression of AT1 receptor mRNA in all groups; (B) lev-
els of expression of AT2 receptor mRNA in all groups; (C) levels
of expression of Bcl-2 protein in all groups. Control group (n = 10);
Cas+P group (n = 8); S-Cas group (n = 9); Cas+T group (n = 10).
*P < 0.05 versus control group; + P < 0.05 versus Cas+P group. Cas+P:
castration + placebo; Cas+T: castration + testosterone replacement;
GAPDH: glyceraldehyde 3-phosphate dehydrogenase; S-Cas: sham
castration.
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Isoproterenol  is  a  non-selective  1-  and  2-adrenoceptor
gonist  that  can  exert  toxic  effects  through  multiple  mecha-
isms,  including  an  increase  in  intracellular  cyclic  adenosine
onophosphate,  calcium  overload,  alterations  in  electro-
hysiological  properties  of  cardiomyocytes,  ischaemia  and
ncreased  oxidative  stress  [11,12].  Isoproterenol  at  high
oses  results  in  an  extensive  amount  of  cardiomyocyte
ecrosis  [13]. Similar  to  results  from  experimental  myocar-
ial  infarction,  signiﬁcant  cardiomyocyte  loss  mediated  by
soproterenol  administration  is  obtained  predominantly  in
he  LV  and  represents  the  initial  insult  that  triggers  the
nset  of  HF.  Weber  et  al.  [14]  reported  that  catecholamines
dministered  at  high  doses  resulted  in  myocardial  ﬁbrosis
nd  signiﬁcant  alterations  in  thick  and  thin  collagen  ﬁbres.
ccordingly,  this  simple  model  can  be  useful  for  examining
herapeutic  potential  in  chronic  HF.
The  protective  effects  of  oestrogen  on  the  cardiovas-
ular  system  have  been  extensively  studied;  however,  few
linical  studies  have  examined  the  relationships  between
ndrogens  and  cardiovascular  disease.  A  negative  correla-
ion  between  testosterone  levels  and  cardiac  function  has
reviously  been  reported  [15]. Men  with  HF  have  lower-
han-normal  testosterone  levels  and  reduced  levels  of  serum
nabolic  hormones,  constituting  strong  markers  for  poor
rognosis,  independent  of  conventional  risk  predictors.  Fur-
hermore,  testosterone  deﬁciency  is  known  to  be  positively
orrelated  with  cardiac  output  in  patients  with  chronic
F;  a  signiﬁcant  improvement  in  this  variable  has  been
bserved  following  testosterone  replacement  therapy  [2,3].
olden  et  al.  reported  that  androgens  are  capable  of
irectly  enhancing  cardiomyocyte  function  in  the  absence
f  other  cardioregulatory  haemodynamic  and  humoral  fac-
ors  [16]. Our  results  are  consistent  with  these  reports,  in
hat  testosterone  deprivation  decreased  further  cardiac  dys-
unction,  while  testosterone  replacement  therapy  improved
ardiac  function  in  isoproterenol-induced  HF.  In  vivo  stud-
es  have  shown  that  augmented  cardiac  contractile  velocity
n  orchidectomized  animals  that  were  given  testosterone
as  associated  with  a  signiﬁcant  alteration  from  the  slower
yosin  heavy  chain    to  the  faster  myosin  heavy  chain    and
nhanced  l-type  calcium-channel  mRNA  accumulation  [17].
The  RAAS  plays  an  important  role  in  the  progression
f  HF.  Angiotensin  II  binds  to  angiotensin  II  receptors
n  the  heart  and  exerts  other  non-haemodynamic  effects
18,19].  Rogers  et  al.  [20]  reported  that  both  castration  and
ihydrotestosterone  (25  mg)  did  not  alter  glomerular  AT1
eceptor  binding  in  rats,  while  a  high  dose  of  dihydrotestos-
erone  (200  mg)  profoundly  decreased  AT1  receptor  binding.
imilarly,  Song  et  al.  [21]  found  that  neither  castration
or  castration  +  testosterone  treatment  affected  AT1  recep-
or  mRNA  or  protein  expression.  In  the  present  study,  we
bserved  that  neither  castration  nor  testosterone  replace-
ent  affected  AT1  receptor  mRNA  expression,  consistent
ith  the  studies  noted  above.
Although  both  AT1  and  AT2  receptors  have  seven  trans-
embrane  domains  typical  of  G  protein-coupled  receptors,
hey  have  different  functional  properties  and  signal  trans-
uction  mechanisms.  Ichihara  et  al.  [22]  demonstrated  that
he  AT2  receptor  is  related  to  cardiac  ﬁbrosis  and  collagen
eposition  induced  by  angiotensin  II  infusion.  Brilla  et  al.
23]  reported  that  angiotensin  II  stimulated  collagen  syn-
hesis  through  both  the  AT1  and  AT2  receptors  in  rat  cardiac
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ﬁbroblasts  and  that  angiotensin  II-induced  inhibition  of  col-
lagenase  activity  was  mediated  by  AT2  receptors.  In  the
present  study,  we  determined  that  castration-induced  ele-
vated  AT2  receptor  mRNA  expression  in  rats  with  HF,  while
testosterone  replacement  suppressed  this  effect.  Likewise,
cardiac  ﬁbrosis  was  decreased  in  the  testosterone  replace-
ment  group  compared  with  in  the  castration  alone  group.
Nakazawa  et  al.  [24]  also  reported  that  castration  increased
AT2  receptor  mRNA  levels  while  testosterone  administration
reversed  this  effect  in  the  urinary  bladder.  Moreover,  Natoli
et  al.  [25]  found  that  collagen  deposition  was  reduced  in
human  aortic  smooth  muscle  cells  incubated  with  testos-
terone.  Changes  in  AT2  receptor  mRNA  expression  in  HF
accompanied  by  changes  in  the  androgen  environment  are
considered  to  be  among  the  important  phenomena  in  cardiac
function.  Androgen  action  on  the  epididymal  angiotensin
system  has  been  suggested  to  be  at  least  partially  mediated
through  cyclooxygenase-1  expression  [26]. Further  exami-
nations  are  necessary  to  clarify  the  crosstalk  mechanisms
between  the  angiotensin  and  androgen  systems  in  HF.
Apoptosis  plays  a  crucial  role  in  normal  development  as
well  as  in  pathophysiology  of  various  tissues.  AT2  recep-
tor  stimulation  was  demonstrated  to  induce  apoptosis  in
many  cell  types.  In  vivo  studies  have  demonstrated  that  AT2
receptors  mediate  vascular  mass  regression  through  stimu-
lation  of  smooth  muscle  cell  apoptosis  [27,28].  Mechanisms
responsible  for  AT2  receptor-mediated  apoptosis  appear  to
be  complex,  particularly  because  AT2  receptors  activate
tyrosine  phosphatases,  including  mitogen-activated  protein
kinase  phosphatase-1  (MKP-1),  and  inactivate  the  signal-
related  extracellular  mitogen-activated  protein  kinases
ERK1  and  ERK2,  resulting  in  Bcl-2  dephosphorylation  and
upregulation  of  Bax  [29]. Boissonneault  [30]  reported  that
gonadectomy-induced  apoptosis  of  the  rat  levator  ani
muscle,  while  Fan  and  Robaire  [31]  demonstrated  that
orchidectomy  induced  apoptosis  in  the  epididymis,  with
androgen  therapy  partially  reversing  this  change.  In  the
present  study,  isoproterenol-induced  cardiac  cell  apoptosis
and  castration  further  aggravated  this  process.  Testosterone
treatment  decreased  cell  death  induced  through  castra-
tion.  These  ﬁndings  suggest  that  alterations  in  the  androgen
environment  have  an  effect  on  cardiac  cell  apoptosis.  As
these  changes  in  apoptosis  and  Bcl-2  are  consistent  with  AT2
receptor  changes,  we  conclude  that  testosterone  affected
apoptosis  through  the  AT2  receptor.
Conclusion
In  conclusion,  castration  increased  AT2  receptor  expression,
cardiac  ﬁbrosis  and  cardiac  cell  apoptosis  in  rats  with  HF,
which  were  reduced  following  testosterone  replacement.
These  changes  were  accompanied  by  signiﬁcant  improve-
ments  in  LV  function.  Our  ﬁndings  imply  that  androgen
replacement  may  have  beneﬁcial  effects  for  male  HF  with
androgen  deﬁciency  by  altering  the  RASS  system.Disclosure of interest
The  authors  declare  that  they  have  no  conﬂicts  of  interest
concerning  this  article.
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